Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Mucosal Immunol. 2019 Aug 15;12(5):1201–1211. doi: 10.1038/s41385-019-0194-9

Table 1.

Patient characteristics

I II III
Number 3 38 20
Age in years, range 13–15 8–18 8–17
Male (n) 1 19 10
Female (n) 2 19 10
Diagnosis
  ulcerative colitis 16 9
  Crohn’s disease 3 20 11
  IBD unclassified 2
Age at diagnosis (years) 7–11 8–18 5–16
Treatment at time of analysis
  no 38 3
  azathioprine 2 7
  mesalazine 2
  infliximab 6
  methotrexate 1 1
  prednisolone 4
  adalimumab 1 3
  6-mercaptopurine 1
Treatment history
  azathioprine 3
  mesalazine 2
  infliximab 3
  methotrexate 1
  prednisolone 3
  adalimumab 3
  6-mercaptopurine
Surgery 3 10

Cohort I, related to Figure 2gi and Supplementary Figure 2; Cohort II, related to Figure 4b and 4f; Cohort III, related to Figure 4a, 4d and 4e.